Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021
Nicola L. Barclay, Edward Burn, Antonella Delmestri, Talita Duarte‐Salles, Asieh Golozar, Wai Yi Man, Eng Hooi Tan, Ilona Tietzova, James N’Dow, Wim P.j. Witjes, Emma Jane Smith, Carla Bezuidenhout, Sarah Collen, Karin Plass, Torsten Blum, Angelika Borkowetz, Peter-Paul Willemse, Philip Cornford, Saeed Dabestani, Maurice Schlief, Juan Gómez Rivas, Anders Bjartell, M. Roobol, Katharina Beyer, Lionne D. F. Venderbos, Sebastiaan Remmers, Daan Nieboer, Raoul Boomsma, Bertrand De Meulder, Charles Auffray, Nesrine Taibi, Ayman Hijazy, Albert Saporta, Johann Pellet, Imran Omar, Lesley Anderson, Steven MacLennan, Sara MacLennan, Valerie Speirs, Solveiga Žibaitė, Moragh Boyle, Charlotte Murray, Dianne Brown, Demi McDonald, Andres Metspalu, Jaak Vilo, Raivo Kolde, Sulev Reisberg, Elena Sügis, Marek Oja, Telver Objärtel, Alberto Briganti, Giorgio Gandaglia, Martina Faticoni, Greta Matteuzzi, Claude Chelala, Louise Jones, Maryam Abdollahyan, Emanuela Gadaleta, Guido Juckeland, Michael Bußmann, Daniel Kotik, Artur Yakimovich, Torsten Bauer, Jens Kollmeier, Jessica Werchan, Rebecca Graebig-Rancourt, Tobias Sjöblom, Chatarina Larsson, Arvid Widenlou Nordmark, Daniel Prieto‐Alhambra, Sara Khalid, Mahkameh Mafi, Danielle Newby, Cheryl Tan, Nikolaus Forgó, Antoni Napieralski, Martina Wimmer, Katharina Haimbuchner, Saskia Kaltenbrunner, K. Hartl, Kseniia Guliaeva, Giuseppe Curigliano, Carmen Criscitiello, Stefania Morganti, Chiara Corti, Elena Dal Zotto, Nadia Harbeck, Julian Koch, Neal Navani, Sam M. Janes, Amyn Bhamani, Stéphane Lejeune, Mario Campone, Jean‐Sébastien Frenel, Kevin Joubel, François C. BocquetScientific2024 · DOI
Breast cancer is the most frequently diagnosed cancer in females globally. However, we know relatively little about trends in males. This study describes United Kingdom (UK) secular trends in breast cancer from 2000 to 2021 for both sexes using primary care Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases. Crude incidence rates (IR) from 2000 to 2021 were 194.4 per 100,000 person-years for females and 1.16 for males. Crude prevalence in 2021 reached 2.1% for females and 0.009% for males, representing a 2.5-fold increase for both sexes over the study period. While female survival has improved significantly due to screening and treatment advances, male patients continue to have worse survival outcomes, highlighting a need for sex-specific strategies.
Introduction
While breast cancer is the most common cancer in women globally, long-term "secular" trends—non-periodic variations over time—are often estimated using cancer registries that may lack a general population denominator. Furthermore, male breast cancer is frequently excluded from large-scale analyses due to its rarity (approximately 1% of cases). This study provides a high-resolution, population-based view of breast cancer across two decades in the UK, examining how age, sex, and public health initiatives have shifted the disease landscape.
Methods
The researchers conducted a population-based cohort study using two major primary care databases: CPRD GOLD (UK-wide) and CPRD Aurum (England). The cohort included over 5.8 million eligible females and 5.5 million males aged 18+ with at least one year of prior data. Diagnostic codes (SNOMED CT) were used to identify incident cases of primary malignant breast cancer. Annual crude incidence rates and prevalence were calculated, and survival probabilities at 1, 5, and 10 years were estimated using the Kaplan–Meier method. Data were mapped to the OMOP Common Data Model (CDM) to facilitate international replication.
Trends in Incidence and Prevalence
The overall crude incidence rate was 194.4 per 100,000 person-years for females and 1.16 for males. By 2021, prevalence reached 2.1% for females and 0.009% for males, a 2.5-fold increase for both sexes since 2000.
Incidence rates of breast cancer per 100,000 person-years for females and males (2000–2021).
A notable "COVID-19 dip" occurred in 2020, where recorded incidence dropped sharply due to suspended screening programs and reduced GP visits during the pandemic. Rates largely recovered by 2021, suggesting the dip was an artifact of healthcare disruption rather than a change in underlying disease biology.
Age-Specific Trends and the "Youth Surge"
Incidence trends varied significantly by age. In women, rates rose and fell in "screening synchronicity" with eligibility ages (50–70 years), confirming that peaks in detection often follow the implementation of screening programs. However, a concerning "youth surge" was observed: incidence more than doubled in women aged 18–29 between 2003 and 2018. This may be linked to increased awareness or lifestyle factors such as earlier puberty leading to longer lifetime estrogen exposure.
Age-stratified incidence rates showing the 'youth surge' in the 18–29 group and screening-related peaks in older cohorts.
In contrast, male incidence continued to climb with age, peaking in the 90+ category, reflecting a different risk profile compared to females.
Survival Outcomes and the Male Disadvantage
Survival for women has improved markedly. Comparing the 2000–2004 cohort to the 2015–2019 cohort, 1-year survival increased by 2.08 percentage points and 5-year survival by 5.39 percentage points. These gains are attributed to earlier diagnosis through screening and improvements in treatment.
However, a persistent "male survival gap" remains. Men have significantly worse outcomes, with a 10-year survival probability of 51.3% compared to 68.4% for women. This disparity likely stems from later diagnoses, higher comorbidity rates at presentation, and the use of treatment protocols primarily designed for postmenopausal women.
Conclusion
This 20-year retrospective highlights the success of UK screening and treatment programs in improving female survival. However, the rising incidence in younger women and the stark survival disadvantage for men underscore critical areas for future research and public health intervention. Specifically, there is a clear need for male-specific diagnostic and treatment strategies to close the survival gap.
Summary updated
Abstract
Breast cancer is the most frequently diagnosed cancer in females globally. However, we know relatively little about trends in males. This study describes United Kingdom (UK) secular trends in breast cancer from 2000 to 2021 for both sexes. We describe a population-based cohort study using UK primary care Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases. There were 5,848,436 eligible females and 5,539,681 males aged 18+ years, with ≥ one year of prior data availability in the study period. We estimated crude breast cancer incidence rates (IR), prevalence and survival probability at one-, five- and 10-years after diagnosis using the Kaplan-Meier method. Analyses were further stratified by age. Crude IR of breast cancer from 2000 to 2021 was 194.4 per 100,000 person-years for females and 1.16 for males. Crude prevalence in 2021 was 2.1% for females and 0.009% for males. Both sexes have seen around a 2.5-fold increase in prevalence across time. Incidence increased with age for both sexes, peaking in females aged 60-69 years and males 90+ . There was a drop in incidence for females aged 70-79 years. From 2003-2019, incidence increased > twofold in younger females (aged 18-29: IR 2.12 in 2003 vs. 4.58 in 2018); decreased in females aged 50-69 years; and further declined from 2015 onwards in females aged 70-89 years. Survival probability for females after one-, five-, and ten-years after diagnosis was 95.1%, 80.2%, and 68.4%, and for males 92.9%, 69.0%, and 51.3%. Survival probability at one-year increased by 2.08% points, and survival at five years increased by 5.39% from 2000-2004 to 2015-2019 for females, particularly those aged 50-70 years. For males, there were no clear time-trends for short-term and long-term survival probability. Changes in incidence of breast cancer in females largely reflect the success of screening programmes, as rates rise and fall in synchronicity with ages of eligibility for such programmes. Overall survival from breast cancer for females has improved from 2000 to 2021, again reflecting the success of screening programmes, early diagnosis, and improvements in treatments. Male breast cancer patients have worse survival outcomes compared to females, highlighting the need to develop male-specific diagnosis and treatment strategies to improve long-term survival in line with females.
BibTeX
@inproceedings{barclay2024trends,
author = {Nicola L. Barclay and Edward Burn and Antonella Delmestri and Talita Duarte‐Salles and Asieh Golozar and Wai Yi Man and Eng Hooi Tan and Ilona Tietzova and James N’Dow and Wim P.J. Witjes and Emma Jane Smith and Carla Bezuidenhout and Sarah Collen and Karin Plass and Torsten Blum and Angelika Borkowetz and Peter-Paul Willemse and Philip Cornford and Saeed Dabestani and Maurice Schlief and Juan Gómez Rivas and Anders Bjartell and M. Roobol and Katharina Beyer and Lionne D. F. Venderbos and Sebastiaan Remmers and Daan Nieboer and Raoul Boomsma and Bertrand De Meulder and Charles Auffray and Nesrine Taibi and Ayman Hijazy and Albert Saporta and Johann Pellet and Imran Omar and Lesley Anderson and Steven MacLennan and Sara MacLennan and Valerie Speirs and Solveiga Žibaitė and Moragh Boyle and Charlotte Murray and Dianne Brown and Demi McDonald and Andres Metspalu and Jaak Vilo and Raivo Kolde and Sulev Reisberg and Elena Sügis and Marek Oja and Telver Objärtel and Alberto Briganti and Giorgio Gandaglia and Martina Faticoni and Greta Matteuzzi and Claude Chelala and Louise Jones and Maryam Abdollahyan and Emanuela Gadaleta and Guido Juckeland and Michael Bußmann and Daniel Kotik and Artur Yakimovich and Torsten Bauer and Jens Kollmeier and Jessica Werchan and Torsten Blum and Rebecca Graebig-Rancourt and Tobias Sjöblom and Chatarina Larsson and Arvid Widenlou Nordmark and Daniel Prieto‐Alhambra and Sara Khalid and Edward Burn and Antonella Delmestri and Mahkameh Mafi and Danielle Newby and Cheryl Tan and Nikolaus Forgó and Antoni Napieralski and Martina Wimmer and Katharina Haimbuchner and Saskia Kaltenbrunner and K. Hartl and Kseniia Guliaeva and Giuseppe Curigliano and Carmen Criscitiello and Stefania Morganti and Chiara Corti and Elena Dal Zotto and Nadia Harbeck and Julian Koch and Neal Navani and Sam M. Janes and Amyn Bhamani and Stéphane Lejeune and Mario Campone and Jean‐Sébastien Frenel and Kevin Joubel and François C. Bocquet},
title = {{Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021}},
booktitle = {Scientific},
year = {2024},
doi = {10.1038/s41598-024-69006-1},
}